Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: Impact of cyclooxygenase selectivity

被引:101
作者
Carbone, LD
Tylavsky, FA
Cauley, JA
Harris, TB
Lang, TF
Bauer, DC
Barrow, KD
Kritchevsky, SB
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA
[2] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA
[3] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA
[4] NIA, Epidemiol Demography & Biometry Program, Bethesda, MD USA
[5] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA
[6] Univ Calif San Francisco, Prevent Sci Grp, San Francisco, CA 94143 USA
关键词
nonsteroidal anti-inflammatory drugs; bone; aspirin; cyclo-oxygenase; elderly;
D O I
10.1359/jbmr.2003.18.10.1795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the Health ABC cohort (n = 2853). Significantly higher BMD was found in users of relative COX-2 selective NSAIDs with aspirin (COX-2/ASA) compared with nonusers. This suggests a role for COX-2/ASA in osteoporosis. Introduction: The purpose of this study was to determine the relationship of nonsteroidal anti-inflammatory drug (NSAID) use, by cyclo-oxygenase selectivity (COX), and aspirin use on bone mineral density (BMD) in participants from the Health, Aging, and Body Composition (Health ABC) population-based cohort. It is known that NSAIDs inhibit the COX enzyme and decrease production of Prostaglandins, which are involved in regulation of bone turnover. COX has two isoforms, COX-1 and COX-2. Production of Prostaglandins associated with bone loss is primarily mediated through the COX-2 pathway. In addition, aspirin may have effects on bone independent of the prostaglandin pathway. Materials and Methods: NSAID (by COX selectivity) and aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men; 43.1% black, 56.9% white; mean age: 73.6 years) from the Health ABC cohort. For the purposes of this analysis, relative COX-1 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of > 1 in whole blood, and relative COX-2 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of < 1 in whole blood. Analysis of covariance, was used to compare BMD across each NSAID use and aspirin use category adjusting for age, race, gender, weight, height, study site, calcium and vitamin D supplementation, Womac score, history of rheumatoid arthritis, history of arthritis other than rheumatoid, and smoking status. Results: After adjustment for possible confounders, current use of relative COX-2 selective NSAIDs with aspirin was associated with higher BMD at the whole body (4.2%, 1.2-7.3 CI) and total hip (4.6%, 0.5-8.8 CI) by DXA and at both trabecular (34.1%, 15.4-52.7 CI) and cortical spine (12.8%, 2.3-23.3 CI) by quantitative computed tomography. Conclusions: Our data suggest that the combination of relative COX-2 selective NSAIDs and aspirin is associated with higher BMD at multiple skeletal sites in men and women.
引用
收藏
页码:1795 / 1802
页数:8
相关论文
共 43 条
  • [1] Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin
    Abate, A
    Yang, G
    Dennery, PA
    Oberle, S
    Schröder, H
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (11) : 1135 - 1142
  • [2] The pleiotropic functions of aspirin: mechanisms of action
    Amin, AR
    Attur, MG
    Pillinger, M
    Abramson, SB
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (3-4) : 305 - 312
  • [3] Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis
    Armour, KE
    Van't Hof, RJ
    Grabowski, PS
    Reid, DM
    Ralston, SH
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) : 2137 - 2142
  • [4] Bauer DC, 1996, J BONE MINER RES, V11, P29
  • [5] Bellamy N, 1995, WOMAC OSTEOARTHRITIS
  • [6] A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
    Brideau, C
    Kargman, S
    Liu, S
    Dallob, AL
    Ehrich, EW
    Rodger, IW
    Chan, CC
    [J]. INFLAMMATION RESEARCH, 1996, 45 (02) : 68 - 74
  • [7] Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
    Catella-Lawson, F
    Reilly, MP
    Kapoor, SC
    Cucchiara, AJ
    DeMarco, S
    Tournier, B
    Vyas, SN
    FitzGerald, GA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) : 1809 - 1817
  • [8] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
    Chesnut, CH
    Silverman, S
    Andriano, K
    Genant, H
    Gimona, A
    Harris, S
    Kiel, D
    LeBoff, M
    Maricic, M
    Miller, P
    Moniz, C
    Peacock, M
    Richardson, P
    Watts, N
    Baylink, D
    [J]. AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) : 267 - 276
  • [9] Chiang N, 1998, J PHARMACOL EXP THER, V287, P779
  • [10] ASPIRIN TRIGGERS PREVIOUSLY UNDESCRIBED BIOACTIVE EICOSANOIDS BY HUMAN ENDOTHELIAL CELL-LEUKOCYTE INTERACTIONS
    CLARIA, J
    SERHAN, CN
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) : 9475 - 9479